Description
A potent, reversible, and competitive HMG-CoA reductase inhibitor (Ki = 1 nM for the open ring acid form of the molecule); inhibits cholesterogenesis in the liver and ileum of normolipidemic rats, cholestyramine-treated rats, and cholesterol-fed rats when administered at a dose of 50 mg/kg; suppresses TNF-induced NF-κB activation (IC50 = ~17 µM), which potentiates apoptosis in human myeloid leukemia cells
Formal name: 2S-methyl-(1S,2,3,7S,8S,8aR)-hexahydro-7-methyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2-H-pyran-2-yl]ethyl]-1-naphthalenyl ester-butanoic acid
Synonyms: Compactin|CS 500|L-637,312|ML 236B|NSC 281245|Statin I
Molecular weight: 390.5
CAS: 73573-88-3
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Small Molecule Inhibitors|Sterol Biosynthesis||Product Type|Biochemicals|Small Molecule Inhibitors|TNF-α/NF-κB Signaling||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Cancer|Cell Signaling|NF-κB Signaling||Research Area|Cancer|Transcription Factors|NF-κB||Research Area|Cardiovascular System|Lipids & Lipoproteins|Cholesterol Metabolism||Research Area|Cardiovascular System|Lipids & Lipoproteins|Lipoproteins||Research Area|Cell Biology|Cell Death|Ferroptosis||Research Area|Cell Biology|Cell Signaling|NF-κB Signaling||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Dyslipidemias||Research Area|Epigenetics, Transcription, & Translation|Transcription Factors
